CorpDev.Org
Deal Intelligence Platform & Services for Global M&A / PE
Big Deal
ABB Signals Multi-Billion Dollar M&A Blitz Following Strategic Divestitures
TL;DR Swiss industrial giant ABB is signaling a shift to multi-billion dollar acquisitions, funded by the $5.4 billion divestiture of its robotics division to SoftBank. Chairman Peter Voser confirmed on March 13, 2026, that the company will target...
TPG Unwinds Intersect Stake in $12 Billion Split Sale to Google: A Blueprint for AI-Era Infrastructure Monetization
TL;DR TPG Rise Climate sold its stake in Intersect's digital power assets to Google for $4.75 billion in cash plus assumed debt, part of a larger $12 billion transaction effective March 10, 2026. The deal carves out assets co-located with Google's...
Ackman Unveils Dual-Listing Strategy to Publicly List Pershing Square, Targeting $10 Billion Raise
TL;DR Bill Ackman's Pershing Square Capital Management has filed for an IPO on the NYSE, aiming to raise $5 billion to $10 billion. The transaction features a novel dual-listing structure, offering shares in a new closed-end fund, Pershing Square...
Tencent Re-Engages in $110 Billion Paramount-WBD Megadeal as Passive Investor Amid Regulatory Headwinds
TL;DR Tencent Holdings is considering a passive investment of several hundred million dollars in Paramount Skydance's $110.9 billion acquisition of Warner Bros. Discovery. This follows its earlier withdrawal of a $1 billion commitment over concerns...
Geopolitical Shock Wave: Latest M&A Delays Tied to Volatility in the Middle East
The tentative rebound in global Mergers & Acquisitions activity, which gained footing in the latter half of 2025, is now encountering significant headwinds driven by the escalating military conflict involving Iran. For dealmakers navigating an...
Explainers
Private Equity
International
International
Tech, Media & Telecom
Financial Services
Health & Life Sciences
UCB Acquires Candid Therapeutics for $2.2 Billion in High-Stakes Bet on ‘Immune Reset’
TL;DR Brussels-based biopharma UCB will acquire Candid Therapeutics for up to $2.2 billion, comprised of a $2.0 billion upfront cash payment and $200 million in milestones. The deal centers on Candid's lead asset, Cizutamig, a T-cell engager...
Sun Pharma Nears $12 Billion Acquisition of Organon: A New Frontier for Indian Pharma
TL;DR Mumbai-based Sun Pharmaceutical Industries Ltd. is finalizing a binding $12 billion offer for Organon & Co., marking the largest overseas acquisition in Indian pharma history. The deal is a strategic pivot for Sun Pharma, moving it from a...
Merck’s $6.7 Billion Bid for Terns Pharma: A Strategic Play for Metabolic Leadership
TL;DR Merck & Co. has launched a $6.7 billion all-cash unsolicited offer for Terns Pharma, a biotech firm specializing in small-molecule drug candidates for metabolic disorders like NASH. The acquisition is a strategic move to accelerate...
Alcon Abandons $430 Million Lensar Deal Citing Regulatory Drag; A Warning Shot for MedTech M&A
TL;DR Alcon terminated its agreement to acquire Lensar for up to $430 million on March 17, 2026, citing a protracted, year-long regulatory review by the Federal Trade Commission (FTC). The FTC opposed the deal, arguing it would eliminate direct...
Medtronic Locks in Full Neurovascular Workflow with $550M Scientia Vascular Acquisition
TL;DR Medtronic announced a definitive agreement on March 10, 2026, to acquire Scientia Vascular for approximately $550 million. The deal targets Scientia's advanced guidewires and catheters, critical for accessing complex neurovascular anatomy...
